Preparation and administration of REGN-EB3 for Ebola virus disease (EVD)
2 August 2022
| Toolkit
Overview
Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with REGN-EB3. The most common adverse events (incidence ≥ 20%) are pyrexia, chills, tachycardia, tachypnoea and vomiting. The rate of infusion of REGN-EB3 may be slowed or interrupted if the patient develops any signs of infusion associated events.
WHO Team
Editors
World Health Organization
Number of pages
3
Reference numbers
WHO Reference Number: WHO/EVD/therapeutics/REGN-EB3/Poster_B/2022.1